Modulating the leptin–adiponectin axis in hepatocytes and adipocytes using low molecular weight fucoidan and high-stability fucoxanthin (LMF-HSFx) has become a therapeutic approach to ameliorate hepatic steatosis, inflammation, fibrosis, and IR [136]. This evidence concerns the gene ADIPOQ and fatty liver disease.